
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech is an innovative Germany-based biotechnology company with a robust oncology pipeline and a first commercialized product, the Pfizer-partnered covid vaccine, Comirnaty. Multiple positive results from Phase 2 trials of pumitamig and gotistobart at the European Lung Cancer Congress (ELCC) 2026 derisk the ongoing and pivotal Phase 3 trials for these drugs and increase confidence in their potential success. Additionally, upcoming updates on the FixVac and BNT122 vaccines in the pipeline could drive further value for shareholders.
Bears say
BioNTech is currently in the early stages of clinical development for its cancer therapeutics and vaccines, and its main commercial product, Comirnaty, is developed in partnership with Pfizer, reducing its potential for revenue growth. The company's financials have also shown a decline in operating cash flow and an increase in debt, further raising concerns about its ability to fund its pipeline and maintain profitability. In addition, competition in the oncology space is rapidly growing, and BioNTech's pipeline is still small and unproven compared to its competitors, with a lack of significant data and a smaller sample size.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares